Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

sector : Health care and social assistance    tags : Vrdn-001    save search

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2023-01-08 (Crawled : 16:20) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K twitter stocktwits trandingview |
Health Care and Social Assistan...
| Email alert Add to watchlist

vrdn-001 ongoing thyroid disease eye trial positive phase 1
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K twitter stocktwits trandingview |
Health Care and Social Assistan...
| | O: -2.49% H: 6.5% C: 1.6%

vrdn-001 ongoing thyroid disease eye trial positive phase 1
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
Published: 2022-10-22 (Crawled : 20:20) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K twitter stocktwits trandingview |
Health Care and Social Assistan...
| Email alert Add to watchlist

vrdn-001 ongoing thyroid disease active meeting eye trial positive
Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-08-15 (Crawled : 11:00) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K twitter stocktwits trandingview |
Health Care and Social Assistan...
| | O: 35.85% H: 26.84% C: 9.95%

vrdn-001 ongoing thyroid disease eye positive phase 1
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
VRDN | $15.17 0.6% 0.59% 580K twitter stocktwits trandingview |
Health Care and Social Assistan...
| | O: 0.1% H: 0.0% C: -3.4%

vrdn-001 eye eye disease trial therapeutics disease phase 1 phase 2
Gainers vs Losers
64% 36%

Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M twitter stocktwits trandingview |
Finance

ZCMD | $2.86 108.76% 52.1% 2.3M twitter stocktwits trandingview |
Commercial Services

INVO | $1.555 104.6% 51.13% 5M twitter stocktwits trandingview |
Health Technology

ISPC | $0.437 105.16% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M twitter stocktwits trandingview |

OST | $0.499 21.38% 45.26% 1.9M twitter stocktwits trandingview |

XPON | News | $3.1 60.62% 37.74% 17M twitter stocktwits trandingview |

TIRX | $0.7 44.39% 30.74% 58M twitter stocktwits trandingview |

BNTC | News | $6.92 44.17% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology

GGE | $0.035 19.86% 29.3% 64M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.